Answers are grounded in this paper and cite their sources.
Combination therapy maintains health-related quality of life in patients with BRAF V600E thyroid cancer, suggesting potential clinical benefits.
Combination therapy of encorafenib plus binimetinib for unresectable BRAF V600-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.
No takes yet. Share an insight, caveat, or question.
Kiyota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: